300942 易瑞生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.1411.5501.993-20.3888.689
总资产报酬率 ROA (%)-0.6810.9221.217-14.0156.814
投入资产回报率 ROIC (%)-0.7481.0051.316-15.4777.659

边际利润分析
销售毛利率 (%)55.79863.98370.62849.92956.506
营业利润率 (%)-22.8042.1199.349-68.98714.283
息税前利润/营业总收入 (%)-2.80411.71012.285-71.06912.577
净利润/营业总收入 (%)-18.1905.8767.411-72.79812.034

收益指标分析
经营活动净收益/利润总额(%)121.24421.19470.94544.059138.511
价值变动净收益/利润总额(%)-10.140-39.103-20.20530.4192.820
营业外收支净额/利润总额(%)-0.41558.026-6.4801.404-3.395

偿债能力分析
流动比率 (X)7.2935.0894.9465.3873.376
速动比率 (X)6.7244.7484.6805.1582.872
资产负债率 (%)39.55340.46240.27837.42524.777
带息债务/全部投入资本 (%)31.73330.90335.66629.32710.962
股东权益/带息债务 (%)205.350213.406178.619234.117763.464
股东权益/负债合计 (%)151.837146.560148.061167.253303.659
利息保障倍数 (X)-0.1411.7583.50564.635-10.167

营运能力分析
应收账款周转天数 (天)165.505139.682136.622113.35747.412
存货周转天数 (天)206.721180.751196.462186.842117.164